CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
LY3023703 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01632579
NCT01632579Phase 1Completed
CompareCT.gov

A Single-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3023703 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Jul 3, 2012·Updated Aug 6, 2018

In Brief

A Phase 1 clinical trial evaluating LY3023703, Placebo, and 1 other intervention for Healthy Volunteers. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This is a phase I study of LY3023703 in healthy participants. The purposes of this study are to look at safety, how well the study drug is tolerated, how much of the study drug gets into the blood stream, and how long it takes the body to get rid of it when given to humans. Information about any side effects that may occur will also be collected. Participants will remain in the study for approximately 3 months. This study is for research purposes only and is not intended to treat any medical condition.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 3, 2012
Enrollment StartJun 1, 2012
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 14.0 years ago

Interventions

LY3023703drug

Administered orally

Placebodrug

Administered orally

Celecoxibdrug

Administered orally